Dyne Therapeutics Inc. (DYN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Levi & Korsinsky Announces an Investigation on Behalf of Dyne Therapeutics, Inc. (DYN) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / September 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Dyne Therapeutics, Inc. ("Dyne Therapeutics, Inc.") (NASDAQ:DYN) concerning possible violations of federal securities laws. Dyne issued a press release on September 3, 2024, "announc[ing] new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.
Investors Who Lost Money on Dyne Therapeutics, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - DYN
NEW YORK, NY / ACCESSWIRE / September 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Dyne Therapeutics, Inc. ("Dyne Therapeutics, Inc.") (NASDAQ:DYN) concerning possible violations of federal securities laws. Dyne issued a press release on September 3, 2024, "announc[ing] new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.
Dyne Therapeutics, Inc. (DYN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / September 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN). Investors who purchased Dyne securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DYN.
DYN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Dyne Therapeutics, Inc.
NEW YORK, NY / ACCESSWIRE / September 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Dyne Therapeutics, Inc. ("Dyne Therapeutics, Inc.") (NASDAQ:DYN) concerning possible violations of federal securities laws. Dyne issued a press release on September 3, 2024, "announc[ing] new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.
The Schall Law Firm In Looking Into Dyne Therapeutics Inc. For Potential Securities Law Violations And Investors Can Reach Out
LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Dyne Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - DYN
NEW YORK, NY / ACCESSWIRE / September 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Dyne Therapeutics, Inc. ("Dyne Therapeutics, Inc.") (NASDAQ:DYN) concerning possible violations of federal securities laws. Dyne issued a press release on September 3, 2024, "announc[ing] new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Dyne Therapeutics, Inc.(DYN) and Encourages Stockholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / September 5, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN). Investors who purchased Dyne securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DYN.
DYN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Dyne Therapeutics, Inc. investment
NEW YORK, NY / ACCESSWIRE / September 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Dyne Therapeutics, Inc. ("Dyne Therapeutics, Inc.") (NASDAQ:DYN) concerning possible violations of federal securities laws. Dyne issued a press release on September 3, 2024, "announc[ing] new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.
Dyne Therapeutics Inc May Have Defrauded The Public And Affected Stockholders Should Join The Schall Law Firm's Inquiry
LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Levi & Korsinsky Reminds Dyne Therapeutics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws – DYN
NEW YORK, NY / ACCESSWIRE / September 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Dyne Therapeutics, Inc. ("Dyne Therapeutics, Inc.") (NASDAQ:DYN) concerning possible violations of federal securities laws. Dyne issued a press release on September 3, 2024, "announc[ing] new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.
Dyne Reports Mixed Data From DMD Study, Key Executives Step Down
DYN's shares plummet following mixed data from its ongoing DMD study. Senior executives of the company step down.
Bronstein, Gewirtz & Grossman, LLC Encourages Dyne Therapeutics, Inc.(DYN) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / September 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN). Investors who purchased Dyne securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DYN.
